Table 2.
Multivariate Analysis of IPI and HIF-1α Protein Expression With PFS and OS in Patients With DLBCL Treated With R-CHOP
| Variable | Progression-Free Survival |
Overall Survival |
||||
|---|---|---|---|---|---|---|
| HR* | 95% CI | P | HR* | 95% CI | P | |
| IPI 3-5 | 2.41 | 1.17 to 4.99 | .018 | 2.21 | 0.99 to 4.89 | .051 |
| HIF1α-positive expression | 0.45 | 0.22 to 0.91 | .026 | 0.45 | 0.21 to 0.98 | .043 |
Abbreviations: IPI, International Prognostic Index; HIF, hypoxia-inducible factor; PFS, progression-free survival; OS, overall survival; DLBCL, diffuse large B-cell lymphoma; R-CHOP, rituximab with cyclophosphamide, doxorubicin, oncovin, and prednisone; HR, hazard ratio.
*
HR greater than 1 indicates a factor with poor prognosis, whereas a ratio of 1 or less indicates a factor with good prognosis.